Adobe Stock
Tremedics, a medical technology company pioneering a stent for diseased aortas in children, has won the 2024 MassChallenge Healthcare Award.
The $25,000 prize was presented at Resolve 2025 in Boston, the culminating event for the 2024 MassChallenge U.S. Early Stage Accelerator Program, which included 128 startups selected from more than 1,300 applications.
Tremedics, a TechFW member since 2018, was recognized for its innovative and groundbreaking work on a stent designed to restore blood flow, seamlessly integrate with tissue and eventually dissolve, allowing for the natural growth of diseased aortas in children.
"The award validates our team's dedication to transforming healthcare and underscores the importance of our work in congenital heart disease,” said Tre Welch, CEO of Tremedics.
The Resolve Awards ceremony featured a startup showcase during which 32 startups presented their innovations across various sectors, including Climate, Dual Use, FinTech, HealthTech and Social Impact. MassChallenge’s U.S. Early Stage accelerator program supports startups through mentorship, resources and industry connections.
Tremedics completed the MassChallenge Accelerator program in September 2024.
Welch’s technology aims to transform treatment for children with congenital heart disease by reducing the number of open-heart surgeries they must endure. The innovation allows a single heart stent to grow with the patient, potentially redefining how the condition is managed and greatly improving outcomes for young patients.
The near future for Tremedics is a pre-clinical study to assess the degradation of the stent, which could lead to filing an Investigational Device Exemption status with the Federal Drug Administration.
Tremedics’ innovation, Welch said, “aligns perfectly with MassChallenge's mission to foster impactful healthcare advancements through innovation and strategic partnerships."